Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Omalizumab
Omalizumab
Omalizumab
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, anti-immunoglobulin E, omalizumab
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of allergic asthma >= 1 year duration and a history consistent with Step 2 or 3 clinical features from the Global Initiative for Asthma guidelines.
- Eligible baseline serum immunoglobulin E (IgE) levels value and body-weight combinations
Exclusion Criteria:
- Documented medical history of anaphylaxis
- Lung disease other than mild to moderate allergic asthma such as chronic obstructive pulmonary disease (COPD)
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Novartis Investigative Site
- Novartis Investigative site
- Novartis investigative site
- Novartis investigative site
- Novartis Investigative site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
1
2
3
Arm Description
Omalizumab 900 mg
Omalizumab 1050 mg
Omalizumab 1200 mg
Outcomes
Primary Outcome Measures
Safety and tolerability of omalizumab assessed by AEs and SAEs
Secondary Outcome Measures
- Pharmacokinetic/pharmacodynamic profile of multiple administrations of omalizumab to patients with mild to moderate allergic asthma - Pre-dose specific IgE levels
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00546143
Brief Title
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
Official Title
Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab
Study Type
Interventional
2. Study Status
Record Verification Date
September 2010
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Novartis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, anti-immunoglobulin E, omalizumab
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Omalizumab 900 mg
Arm Title
2
Arm Type
Experimental
Arm Description
Omalizumab 1050 mg
Arm Title
3
Arm Type
Experimental
Arm Description
Omalizumab 1200 mg
Intervention Type
Drug
Intervention Name(s)
Omalizumab
Other Intervention Name(s)
Xolair, IGE025
Intervention Type
Drug
Intervention Name(s)
Omalizumab
Other Intervention Name(s)
Xolair, IGE025
Intervention Type
Drug
Intervention Name(s)
Omalizumab
Other Intervention Name(s)
Xolair, IGE025
Primary Outcome Measure Information:
Title
Safety and tolerability of omalizumab assessed by AEs and SAEs
Secondary Outcome Measure Information:
Title
- Pharmacokinetic/pharmacodynamic profile of multiple administrations of omalizumab to patients with mild to moderate allergic asthma - Pre-dose specific IgE levels
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of allergic asthma >= 1 year duration and a history consistent with Step 2 or 3 clinical features from the Global Initiative for Asthma guidelines.
Eligible baseline serum immunoglobulin E (IgE) levels value and body-weight combinations
Exclusion Criteria:
Documented medical history of anaphylaxis
Lung disease other than mild to moderate allergic asthma such as chronic obstructive pulmonary disease (COPD)
Other protocol-defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Novartis investigative site
Official's Role
Principal Investigator
Facility Information:
Facility Name
Novartis Investigative Site
City
Berlin
Country
Germany
Facility Name
Novartis Investigative site
City
Hamburg
Country
Germany
Facility Name
Novartis investigative site
City
Hannover
Country
Germany
Facility Name
Novartis investigative site
City
Mainz
Country
Germany
Facility Name
Novartis Investigative site
City
Bloemfontein
Country
South Africa
12. IPD Sharing Statement
Citations:
PubMed Identifier
24657236
Citation
Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18.
Results Reference
derived
Learn more about this trial
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
We'll reach out to this number within 24 hrs